PCRI's CEO, Alex Scholz, asks medical oncologist, Mark Scholz, MD, about the distinctions between Gleason 4+3=7 and 3+4=7, temporary versus permanent seed implants, and the significance of seminal vesicle invasion.

0:05 What treatment options are available for men with Gleason 7 (3+4, not 4+3) prostate cancer?

1:23 How should Gleason 7 (4+3) be treated?

3:22 What seed implant therapies do you suggest, temporary (HDR) or permanent?

4:07 How should cancer in the seminal vesicles be treated and what are the risks?

5:23 What are the next steps after discovering spread to the seminal vesicles?

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #Prostate #MarkScholzMD

свернуть